Equities research analysts expect that Aratana Therapeutics Inc (NASDAQ:PETX) will announce earnings of ($0.10) per share for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Aratana Therapeutics’ earnings, with estimates ranging from ($0.11) to ($0.09). Aratana Therapeutics reported earnings per share of ($0.19) in the same quarter last year, which would indicate a positive year over year growth rate of 47.4%. The company is expected to issue its next earnings report on Thursday, May 2nd.

According to Zacks, analysts expect that Aratana Therapeutics will report full year earnings of ($0.32) per share for the current financial year, with EPS estimates ranging from ($0.39) to ($0.29). For the next financial year, analysts anticipate that the company will report earnings of $0.12 per share, with EPS estimates ranging from ($0.06) to $0.31. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Aratana Therapeutics.

Aratana Therapeutics (NASDAQ:PETX) last posted its quarterly earnings results on Tuesday, March 12th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.06). The company had revenue of $4.91 million during the quarter, compared to analyst estimates of $6.53 million. Aratana Therapeutics had a negative return on equity of 14.78% and a negative net margin of 41.57%.

PETX has been the subject of a number of research reports. TheStreet cut shares of Aratana Therapeutics from a “c-” rating to a “d+” rating in a report on Monday, March 4th. Zacks Investment Research upgraded shares of Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $6.50 price target for the company in a report on Wednesday, January 2nd. William Blair cut shares of Aratana Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.14 price target for the company. in a report on Thursday, January 24th. BidaskClub cut shares of Aratana Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, January 11th. Finally, Stifel Nicolaus cut shares of Aratana Therapeutics from a “buy” rating to a “hold” rating and reduced their price target for the stock from $8.00 to $5.00 in a report on Friday, January 11th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Aratana Therapeutics presently has a consensus rating of “Hold” and an average target price of $6.41.

Several institutional investors have recently added to or reduced their stakes in the business. Truvestments Capital LLC bought a new position in shares of Aratana Therapeutics in the first quarter valued at $25,000. Toth Financial Advisory Corp bought a new position in shares of Aratana Therapeutics in the first quarter valued at $30,000. Adams Asset Advisors LLC bought a new position in shares of Aratana Therapeutics in the first quarter valued at $36,000. Raymond James & Associates bought a new position in shares of Aratana Therapeutics in the fourth quarter valued at $65,000. Finally, Campbell & CO Investment Adviser LLC bought a new position in shares of Aratana Therapeutics in the fourth quarter valued at $88,000. 68.13% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:PETX traded down $0.03 during trading hours on Friday, reaching $3.50. The company had a trading volume of 181,832 shares, compared to its average volume of 260,426. The stock has a market capitalization of $171.41 million, a price-to-earnings ratio of -10.94 and a beta of 1.36. Aratana Therapeutics has a twelve month low of $3.30 and a twelve month high of $7.16.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States.

Featured Story: How does the Federal Reserve determine interest rates?

Get a free copy of the Zacks research report on Aratana Therapeutics (PETX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.